Gene Therapy Partnering Terms and Agreements

Published: May 2014
No. of Pages: 495
   

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in gene therapypartnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Gene therapypartnering contract documents
  • Top gene therapy deals by value

The Gene Therapy Partnering Terms and Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2007 including financial terms where available including over 300 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of gene therapy and oligonucleotide dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in gene therapy dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading gene therapy deals since 2009. Deals are listed by headline value and by big pharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record providing easy access to each contract document. The report also includes oligonucleotide and aptamers deals and alliances.

Chapter 6 provides a comprehensive and detailed review of technology specific (gene therapy and oligonucleotide) partnering deals signed and announced since 2009. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand

The report also includes numerous tables and figures that illustrate the trends and activities in gene therapy partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gene therapy technologies and products.

The report also includes a comprehensive appendix listing gene therapy deals by Company A-Z, deal type, stage of development and therapy focus.

Report scope

Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.

Gene Therapy Partnering Terms and Agreements includes:

  • Trends in gene therapy dealmaking in the biopharma industry since 2009
  • Analysis of gene therapy deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life gene therapy deals
  • Access to over 200 gene therapy contract documents
  • The leading antibody deals by value since 2009
  • Most active gene therapy dealmakers since 2009
  • The leading gene therapy partnering resources

In Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Gene Therapy Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of gene therapy deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of gene therapy agreements with numerous real life case studies
  • Comprehensive access to 200 actual gene therapy deals entered into by the world’s biopharma companies
  • Detailed access to actual gene therapy contracts enter into by the leading fifty bigpharma
  • Insight into the terms included in gene therapy agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Gene Therapy Partnering Terms and Agreements

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in gene therapy dealmaking
2.1. Introduction
2.2. Gene therapy partnering over the years
2.3. Big pharma gene therapy dealmaking activity
2.4. Most active in gene therapy partnering
2.5. Gene therapy partnering by deal type
2.6. Gene therapy partnering by disease type
2.7. Partnering by industry sector
2.8. Average deal terms for gene therapy partnering
2.8.1 Gene therapy headline values
2.8.2 Gene therapy upfront payments
2.8.3 Gene therapy milestone payments
2.8.4 Gene therapy royalty rates
2.9. The anatomy of gene therapy partnering
2.9. The anatomy of a gene therapy deal
2.9.a. Case study 1: Novartis, Quark Pharmaceuticals - 2010
2.9.b. Case study 2: OncoGenex Pharmaceuticals, Teva Pharmaceuticals: Dec 2009

Chapter 3 – Leading gene therapy deals
3.1. Introduction
3.2. Top gene therapy deals by value
3.3. Top big pharma gene therapy deals by value

Chapter 4 – Big pharma gene therapy deals
4.1. Introduction
4.2. How to use big pharma gene therapy partnering deals
4.3. Big pharma gene therapy partnering company profiles
Abbott
Amgen
AstraZeneca
Baxter International
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Dainippon Sumitomo
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Pfizer
Roche
Sanofi
Sanofi-Aventis
Shionogi
Shire
Servier
Teva

Chapter 5– Gene therapy partnering contracts directory
5.1. Introduction
5.2. Company A-Z
Alnylam Pharmaceuticals
Amgen
Amsterdam Molecular Therapeutics
Applied Genetic Technologies
Asklepios Biopharmaceutical
AstraZeneca
Atlantic Healthcare
AVI Pharma
Bristol-Myers Squibb
Celladon
Charleys Fund
Chiesi Farmaceutici
Cornell University
DeCODE Genetics
Defense Threat Reduction Agency
Digna Biotech
Dynavax Technologies
Embryome Sciences
Enzon Pharmaceuticals
GenVec
Genzyme
Georgetown University
GlaxoSmithKline
Icagen
Idera Pharmaceuticals
Institut Pasteur
Isis Pharmaceuticals
Lonza
Marina Biotech
MDRNA
Merck KGaA
MorphoSys
NanoViricides
National Institutes of Health
Neurologix
Novartis
OncoGenex Pharmaceuticals
OncoGenex Technologies
Quark Pharmaceuticals
Regulus Therapeutics
Reproductive Genetics Institute
Response Genetics
RiboTask
Saga Investments
Santaris
Stanford University
Targeted Genetics
Teva Pharmaceutical Industries
TheraCour Pharma
UniQure
University of California San Francisco
Xencor
5.3. By deal type
Asset purchase
Assignment
Co-development
Collaborative R&D
Contract service
Co-promotion
Development
Equity purchase
Grant
Licensing
Loan
Manufacturing
Marketing
Option
Research
Sub-license
Supply
Technology transfer
5.4. By stage of development
Discovery
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
5.5. By therapy area
Cardiovascular
Central Nervous System
Gastrointestinal
Genetic disorders
Genitourinary
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Psychiatry
Respiratory
Sensory organs

Chapter 6 – Gene therapy dealmaking by technology type
6.1. Introduction
6.2. Deals by gene therapy technology type
Gene therapy
Oligonucleotide

Appendices
Appendix 1- Gene therapy dealmaking by Company A-Z
Appendix 2 - Gene therapy dealmaking by deal type
Appendix 3 - Gene therapy dealmaking by stage of development
Appendix 4 - Gene therapy dealmaking by therapy area
Appendix 5 – Gene therapy partnering resource center
Online gene therapy partnering
Gene therapy partnering events
Further reading on gene therapy dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Technology Reports

List of Figures

Figure 1: Gene therapy partnering since 2009
Figure 2: Bigpharma – top 50 – gene therapy deals 2009 to 2014
Figure 3: Big pharma gene therapy deal frequency – 2009 to 2014
Figure 4: Active gene therapy dealmaking activity– 2009 to 2014
Figure 5: Gene therapy partnering by deal type since 2009
Figure 6: Gene therapy partnering by disease type since 2009
Figure 7: Gene therapy partnering by technology type since 2009
Figure 8: Gene therapy deals with a headline value
Figure 9: Gene therapy deal headline value distribution, US$million – discovery stage
Figure 10: Gene therapy deal headline value distribution, US$million – preclinical stage
Figure 11: Gene therapy deal headline value distribution, US$million – phase I stage
Figure 12: Gene therapy deal headline value distribution, US$million – phase II stage
Figure 13: Gene therapy deal headline value distribution, US$million – phase III stage
Figure 14: Gene therapy deal headline value distribution, US$million – regulatory stage
Figure 15: Gene therapy deal headline value distribution, US$million – marketed stage
Figure 16: Summary median headline value by stage of development, 2009-2014
Figure 17: Gene therapy deals with upfront payment values
Figure 18: Gene therapy deal upfront payment distribution, US$million – discovery stage
Figure 19: Gene therapy deal upfront payment distribution, US$million – preclinical stage
Figure 20: Gene therapy deal upfront payment distribution, US$million – phase I stage
Figure 21: Gene therapy deal upfront payment distribution, US$million – phase II stage
Figure 22: Gene therapy deal upfront payment distribution, US$million – phase III stage
Figure 23: Gene therapy deal upfront payment distribution, US$million – regulatory stage
Figure 24: Gene therapy deal upfront payment distribution, US$million – marketed stage
Figure 25: Summary median upfront payments by stage of development, 2009-2014
Figure 26: Gene therapy deals with milestone payments
Figure 27: Gene therapy deal milestone distribution, US$million – discovery stage
Figure 28: Gene therapy deal milestone distribution, US$million – preclinical stage
Figure 29: Gene therapy deal milestone distribution, US$million – phase I stage
Figure 30: Gene therapy deal milestone distribution, US$million – phase II stage
Figure 31: Gene therapy deal milestone distribution, US$million – phase III stage
Figure 32: Gene therapy deal milestone distribution, US$million – regulatory stage
Figure 33: Gene therapy deal milestone distribution, US$million – marketed stage
Figure 34: Gene therapy deals with royalty rates, %
Figure 35: Gene therapy deal royalty rate distribution, US$million – discovery stage
Figure 36: Gene therapy deal royalty rate distribution, US$million – preclinical stage
Figure 37: Gene therapy deal royalty rate distribution, US$million – phase I stage
Figure 38: Gene therapy deal royalty rate distribution, US$million – phase II stage
Figure 39: Gene therapy deal royalty rate distribution, US$million – phase III stage
Figure 40: Gene therapy deal royalty rate distribution, US$million – regulatory stage
Figure 41: Gene therapy deal royalty rate distribution, US$million – marketed stage
Figure 42: Summary median royalty rate by stage of development, 2009-2014
Figure 43: Components of the typical gene therapy deal structure
Figure 44: Top gene therapy deals by value since 2009
Figure 45: Top gene therapy deals by value since 2009
Figure 46: Online partnering resources
Figure 47: Forthcoming partnering events

Published By: Current Partnering
Product Code: Current Partnering37


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:

  • Discovery Stage Partnering Terms and Agreements

    The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare com...

  • Monoclonal Antibodies Partnering Terms and Agreements

    The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licen...

  • Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

    The Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma compani...

  • Vaccine Partnering Terms and Agreements

    The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in vaccine a...

  • Drug Delivery Partnering Terms and Agreements

    The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.The report p...

  • Diagnostics Partnering Terms and Agreements

    The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.The report provides a detai...

  • Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

    The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by th...

  • Cancer Diagnostics Partnering Terms and Agreements

    The Cancer Diagnostics Partnering Agreements report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in cancer diagnostics par...

  • Cancer Vaccine Partnering Terms and Agreements

    The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in cancer vaccine partnering deal...

  • Infectives Vaccine Partnering Terms and Agreements

    The Infectives vaccine partnering terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectives vaccine partnering deals. The majority of deals are development stage whereby the licensee obtai...


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Biotechnology market as per your needs. Get the best of Biotechnology research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100